What changed in Q4 2026
Compared with Q3 2026, using the current CMS release of each quarter (including CMS revisions).
- Drug payment limits changed
- 778
- New drug codes
- 28
- Terminated drug codes
- 13
- Crosswalk NDC changes
- 617
Your watchlist
Codes you follow, saved in this browser only. Changes for them this quarter appear here.
Your watchlist is empty.
Largest payment-limit increases
Drug codes whose Part B payment limit per billing unit rose the most from the previous quarter (top 25 by percent).
| HCPCS | Description | Previous | Now | Change |
|---|---|---|---|---|
| J9304 | Inj. pemetrexed, 10 mgper 10 MG | $7.994 | $92.505 | +1057.2% |
| J3489 | Zoledronic acid 1mgper 1 MG | $3.361 | $17.673 | +425.8% |
| J2516 | Inj, pentamidine isethionateper 1 MG | $0.160 | $0.482 | +201.2% |
| J1920 | Inj, labetalol hcl, 5mgper 5 MG | $0.218 | $0.588 | +169.7% |
| Q9965 | Locm 100-199mg/ml iodine,1mlper 1 ML | $0.750 | $1.787 | +138.3% |
| Q5120 | Inj pegfilgrastim-bmez 0.5mgper 0.5 MG | $132.096 | $302.247 | +128.8% |
| J3379 | Inj, valproate sod, 5 mgper 5 MG | $0.014 | $0.032 | +128.6% |
| J1885 | Ketorolac tromethamine injper 15 MG | $0.286 | $0.569 | +99% |
| J1171 | Inj, hydromorphone, 0.1 mgper 0.1 MG | $0.136 | $0.224 | +64.7% |
| J9263 | Oxaliplatinper 0.5 MG | $0.055 | $0.087 | +58.2% |
| J2151 | Inj, mannitol, 250 mgper 250 MG | $0.071 | $0.112 | +57.7% |
| Q5112 | Inj ontruzant 10 mgper 10 MG | $20.989 | $32.791 | +56.2% |
| J2175 | Meperidine hydrochl /100 mgper 100 MG | $6.339 | $9.652 | +52.3% |
| J2596 | Vasopressin (long grove) 1 uper 1 UNIT | $1.134 | $1.712 | +51% |
| J2562 | Plerixafor injectionper 1 MG | $28.489 | $42.943 | +50.7% |
| J0872 | Daptomycin (xellia) unrefrigper 1 MG | $0.042 | $0.060 | +42.9% |
| J1598 | Inj glycopyrrolate fres kabiper 0.1 MG | $1.342 | $1.904 | +41.9% |
| J0500 | Dicyclomine injectionper 20 MG | $8.520 | $12.061 | +41.6% |
| J2506 | Inj pegfilgrast ex bio 0.5mgper 0.5 MG | $143.233 | $201.241 | +40.5% |
| J0138 | Inj acetaminoph 10mg/ibu 3mgper 10 MG/3MG | $0.092 | $0.129 | +40.2% |
| J7329 | Inj, trivisc 1 mgper 1 MG | $3.036 | $4.207 | +38.6% |
| J0133 | Acyclovir injectionper 5 MG | $0.035 | $0.048 | +37.1% |
| J0456 | Azithromycinper 500 MG | $1.889 | $2.571 | +36.1% |
| J1956 | Levofloxacin injectionper 250 MG | $1.909 | $2.565 | +34.4% |
| J2690 | Procainamide hcl injectionper 1 GM | $295.361 | $394.868 | +33.7% |
Largest payment-limit decreases
Drug codes whose payment limit fell the most (top 25 by percent). Large drops often follow new competition, such as biosimilar or generic entry.
| HCPCS | Description | Previous | Now | Change |
|---|---|---|---|---|
| J9305 | Inj. pemetrexed nos 10mgper 10 MG | $6.952 | $1.230 | -82.3% |
| J3105 | Terbutaline sulfate injper 1 MG | $2.820 | $1.000 | -64.5% |
| Q5119 | Inj ruxience, 10 mgper 10 MG | $16.160 | $5.792 | -64.2% |
| J8522 | Capecitabine, oral, 50 mgper 50 MG | $0.080 | $0.029 | -63.8% |
| J0877 | Inj, daptomycin (hospira)per 1 MG | $0.057 | $0.022 | -61.4% |
| J8700 | Temozolomideper 5 MG | $0.425 | $0.208 | -51.1% |
| J2778 | Ranibizumab injectionper 0.1 mg | $51.090 | $26.384 | -48.4% |
| J9264 | Paclitaxel protein boundper 1 MG | $6.586 | $3.640 | -44.7% |
| J7631 | Cromolyn sodium noncomp unitper 10 MG | $0.691 | $0.385 | -44.3% |
| J3000 | Streptomycin injectionper 1 GM | $26.883 | $16.407 | -39% |
| J9033 | Inj, bendamustine (nos) 1mgper 1 MG | $2.960 | $1.846 | -37.6% |
| J9261 | Nelarabine injectionper 50 MG | $65.407 | $40.872 | -37.5% |
| J7510 | Prednisolone oral per 5 mgper 5 MG | $0.777 | $0.498 | -35.9% |
| J9293 | Mitoxantrone hydrochl / 5 mgper 5 MG | $29.702 | $19.418 | -34.6% |
| J1790 | Droperidol injectionper up to 5 MG | $8.124 | $5.348 | -34.2% |
| Q5156 | Inj, tocilizumab-anoh, 1 mgper 1 MG | $4.692 | $3.098 | -34% |
| J2251 | Inj midazolam in 0.9% naclper 1 MG | $0.117 | $0.078 | -33.3% |
| J9025 | Azacitidine injectionper 1 MG | $0.401 | $0.269 | -32.9% |
| J2599 | Inj vasopressin (am reg) 1 uper 1 UNIT | $0.834 | $0.574 | -31.2% |
| J1560 | Gamma globulin > 10 cc injper 10 CC | $162.519 | $118.153 | -27.3% |
| J7605 | Arformoterol non-comp unitper 15 mcg | $0.742 | $0.542 | -27% |
| J3360 | Diazepam injectionper 5 MG | $6.854 | $5.069 | -26% |
| J1190 | Dexrazoxane hcl injectionper 250 MG | $41.441 | $30.832 | -25.6% |
| J2246 | Inj, micafungin (baxter)per 1 MG | $0.448 | $0.334 | -25.4% |
| J9351 | Topotecan injectionper 0.1 MG | $2.759 | $2.067 | -25.1% |
New drug codes
Drug-related HCPCS codes first appearing in this quarter’s CMS file. A new permanent code often replaces billing under an unclassified code (such as J3490, J9999, or C9399) — review claims you billed that way.
- C9311 Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)Added Oct 1, 2026
- C9312 Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mgAdded Oct 1, 2026
- C9313 Injection, pivekimab sunirine-pvzy, 0.01 mgAdded Oct 1, 2026
- J0014 Cocaine hydrochloride nasal solution (goprelto), 1 mgAdded Oct 1, 2026
- J0643 Injection, leucovorin calcium, not otherwise specified, 1 mgAdded Oct 1, 2026
- J0644 Injection, leucovorin calcium (avyxa), 1 mgAdded Oct 1, 2026
- J0871 Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mgAdded Oct 1, 2026
- J1757 Injection, tividenofusp alfa-eknm, 1 mgAdded Oct 1, 2026
- J1818 Injection, pegzilarginase-nbln, 0.05 mgAdded Oct 1, 2026
- J1946 Injection, furosemide (lasix onyu), 1 mgAdded Oct 1, 2026
- J1947 Injection, furosemide (furoscix), 1 mgAdded Oct 1, 2026
- J1957 Injection, levetiracetam, 5 mgAdded Oct 1, 2026
- J1958 Injection, levetiracetam in sodium chloride, 5 mgAdded Oct 1, 2026
- J3268 Injection, delafloxacin, 1 mgAdded Oct 1, 2026
- J3406 Injection, omidubicel-onlv, per therapeutic doseAdded Oct 1, 2026
- J7524 Mycophenolate mofetil, oral, 5 mgAdded Oct 1, 2026
- J7526 Injection, mycophenolate mofetil, 5 mgAdded Oct 1, 2026
- J7529 Mycophenolate mofetil, for suspension, oral, 5 mgAdded Oct 1, 2026
- J7530 Mycophenolate mofetil (myhibbin), oral suspension, 5 mgAdded Oct 1, 2026
- J7531 Prednisolone sodium phosphate, orally disintegrating tablet, 1 mgAdded Oct 1, 2026
- J9066 Injection, bendamustine hydrochloride (avyxa), 1 mgAdded Oct 1, 2026
- J9186 Injection, etoposide (avyxa), 1 mgAdded Oct 1, 2026
- J9187 Injection, etoposide, 1 mgAdded Oct 1, 2026
- J9191 Injection, fluorouracil (avyxa), 10 mgAdded Oct 1, 2026
- J9192 Injection, fluorouracil, 10 mgAdded Oct 1, 2026
- J9362 Injection, trabectedin, 0.01 mgAdded Oct 1, 2026
- Q5172 Injection, filgrastim-laha (filkri), biosimilar, 1 microgramAdded Oct 1, 2026
- Q5173 Injection, denosumab-adet (ponlimsi), biosimilar, 1 mgAdded Oct 1, 2026
Terminated drug codes
Drug-related codes with a termination date recorded this quarter. Check the CMS cross-reference on each code page.
- C9046 Cocaine hydrochloride nasal solution (goprelto), 1 mgTerminated Sep 30, 2026
- C9310 Injection, leucovorin calcium (avyxa), 1 mgTerminated Sep 30, 2026
- C9462 Injection, delafloxacin, 1 mgTerminated Sep 30, 2026
- J0640 Injection, leucovorin calcium, per 50 mgTerminated Sep 30, 2026
- J1941 Injection, furosemide (furoscix), 20 mgTerminated Sep 30, 2026
- J1953 Injection, levetiracetam, 10 mgTerminated Sep 30, 2026
- J7514 Mycophenolate mofetil (myhibbin), oral suspension, 100 mgTerminated Sep 30, 2026
- J7517 Mycophenolate mofetil, oral, 250 mgTerminated Sep 30, 2026
- J7519 Injection, mycophenolate mofetil, 10 mgTerminated Sep 30, 2026
- J7528 Mycophenolate mofetil, for suspension, oral, 100 mgTerminated Sep 30, 2026
- J9181 Injection, etoposide, 10 mgTerminated Sep 30, 2026
- J9190 Injection, fluorouracil, 500 mgTerminated Sep 30, 2026
- J9352 Injection, trabectedin, 0.1 mgTerminated Sep 30, 2026
Payment limit file membership
Codes added to or removed from the CMS Part B payment limit file compared with the previous quarter.
Added (37)
- J0014 Cocaine hcl nasal (goprelto)
- J0528 Inj fosfomycin disodium 20mg
- J0643 Inj leucovorin calcium 1 mg
- J0644 Inj, leucovorin cal (avyxa)
- J0716 Centruroides immune f(ab)
- J0841 Inj crotalidae im f(ab')2 eq
- J0871 Inj, daptomycin (endo) 1mg
- J1289 Narsoplimab-wuug, 1 mg
- J1577 Inj, qivigy, 100mg
- J1737 Inj meloxicam (azurity) 1mg
- J1957 Injection levetiracetam 5 mg
- J1958 Inj levetirac sodi chlo 5 mg
- J2361 Inj depemokimab-ulaa 1 mg
- J2374 Apraclonidine hcl opht 0.1ml
- J2789 Riboflavin epioxa/hd<=2ml
- J3268 Injection, delafloxacin
- J3404 Inj zopapogene per ther dose
- J3405 Inj onase abepar-brve treat
- J7524 Mycophenol mofetil oral 5 mg
- J7526 Inj mycophenola mofetil 5 mg
- J7529 Mycop mofetil susp oral 5 mg
- J7530 Mycophenolat (myhibbin) 5 mg
- J8541 Oral, hemady, 0.25 mg
- J9186 Inj etoposide (avyxa), 1 mg
- J9187 Inj, etoposide, 1 mg
- J9191 Inj fluorouracil (avyxa)10mg
- J9192 Inj, fluorouracil, 10 mg
- J9275 Inj cosibelimab-ipdl, 2 mg
- J9318 Inj romidepsin non-lyo 0.1mg
- J9361 Inj, efbemalenograstim alfa-
- J9362 Inj, trabectedin, 0.01 mg
- Q0166 Granisetron hcl 1 mg oral
- Q2058 Obecbtge autol up to 400 mil
- Q5161 Inj, denosumab-kyqq, 1 mg
- Q5167 Inj, denosumab-qbde, 1 mg
- Q5168 Inj. nufymco, 0.1 mg
- Q5169 Inj, armlupeg, 0.5 mg
Removed (10)
- J0640 Leucovorin calcium injection
- J1953 Levetiracetam injection
- J7514 Mycophenol (myhibbin) 100 mg
- J7517 Mycophenolate mofetil oral
- J7519 Inj. mycophenolate mofetil
- J7528 Mycophen mofetil for susp
- J9181 Etoposide injection
- J9190 Fluorouracil injection
- J9352 Injection trabectedin 0.1mg
- J9394 Inj, fulvestrant (fresenius)
NDC–HCPCS crosswalk changes
NDC-to-code pairs added to or removed from the CMS ASP crosswalk between Q3 2026 and Q4 2026.
| HCPCS | NDCs added | NDCs removed | Examples |
|---|---|---|---|
| J1953 | 0 | 56 | − 67457-0255-10 · − 63323-0400-44 · − 70860-0604-82 |
| J7517 | 0 | 43 | − 00093-7334-01 · − 00004-0260-43 · − 50268-0557-15 |
| J1958 | 40 | 0 | + 14789-0330-15 · + 67457-0255-10 · + 65145-0175-10 |
| J0640 | 0 | 35 | − 71288-0162-30 · − 68462-0767-35 · − 70436-0116-82 |
| J0643 | 35 | 0 | + 70436-0119-80 · + 68001-0418-38 · + 70436-0120-80 |
| J7524 | 35 | 0 | + 00004-0260-43 · + 59651-0624-01 · + 67877-0266-01 |
| J9190 | 0 | 30 | − 68001-0524-30 · − 63323-0117-18 · − 63323-0117-10 |
| J9192 | 28 | 0 | + 63323-0117-51 · + 63323-0117-58 · + 70700-0188-22 |
| J9181 | 0 | 20 | − 71288-0175-05 · − 71288-0176-25 · − 63323-0104-06 |
| J9187 | 20 | 0 | + 63323-0104-05 · + 00143-9512-01 · + 63323-0104-06 |
| J1957 | 15 | 0 | + 63323-0400-05 · + 72572-0360-25 · + 55150-0177-05 |
| J3246 | 0 | 7 | − 25208-0002-03 · − 25208-0002-02 · − 25208-0001-04 |
| J7512 | 7 | 0 | + 68788-8819-01 · + 68788-8663-08 · + 68788-8858-01 |
| J7519 | 0 | 6 | − 71288-0803-92 · − 71288-0803-21 · − 67457-0386-81 |
| J7526 | 6 | 0 | + 67457-0386-81 · + 00004-0298-09 · + 42023-0172-04 |
| J7529 | 6 | 0 | + 72603-0751-01 · + 00527-5160-82 · + 23155-0848-51 |
| J9171 | 2 | 3 | + 43066-0048-16 · + 43066-0046-08 · − 16729-0267-64 |
| J0696 | 0 | 4 | − 66794-0212-42 · − 66794-0211-42 · − 66794-0215-15 |
| J2248 | 4 | 0 | + 42658-0023-01 · + 42658-0022-01 · + 42658-0023-02 |
| J2404 | 4 | 0 | + 42571-0394-89 · + 70069-0875-10 · + 70069-0876-10 |
| J2704 | 3 | 1 | + 71288-0729-21 · + 71288-0730-51 · + 71288-0731-53 |
| J3285 | 0 | 4 | − 42023-0206-01 · − 42023-0207-01 · − 42023-0209-01 |
| J7528 | 0 | 4 | − 23155-0848-51 · − 59651-0646-26 · − 67877-0230-22 |
| J9217 | 4 | 0 | + 00074-3346-55 · + 00074-3473-55 · + 00074-3683-55 |
| Q0162 | 4 | 0 | + 62135-0350-05 · + 68788-9559-01 · + 68788-8666-03 |
| Q0167 | 0 | 4 | − 60687-0375-21 · − 60687-0375-01 · − 60687-0386-21 |
| J0290 | 1 | 2 | + 72572-0093-10 · − 00781-3400-95 · − 00781-9401-95 |
| J0644 | 3 | 0 | + 83831-0147-05 · + 83831-0148-35 · + 83831-0149-50 |
| J1200 | 3 | 0 | + 42571-0337-87 · + 42571-0511-56 · + 83634-0781-01 |
| J1250 | 3 | 0 | + 00409-1100-10 · + 00409-0151-10 · + 00409-0025-10 |
| J1920 | 1 | 2 | + 83301-0059-01 · − 72611-0734-01 · − 72611-0738-01 |
| J2260 | 3 | 0 | + 65145-0176-10 · + 70069-0872-10 · + 70069-0873-10 |
| J9075 | 3 | 0 | + 68001-0695-32 · + 68001-0696-32 · + 68001-0694-27 |
| J0461 | 0 | 2 | − 00409-4910-34 · − 00409-4911-34 |
| J0475 | 0 | 2 | − 67457-0563-20 · − 67457-0562-20 |
| J0770 | 2 | 0 | + 00143-9443-12 · + 00143-9443-01 |
| J0872 | 2 | 0 | + 72572-0158-01 · + 00143-9445-01 |
| J0877 | 0 | 2 | − 72572-0158-01 · − 00143-9445-01 |
| J0885 | 2 | 0 | + 55513-0267-20 · + 55513-0126-20 |
| J1163 | 0 | 2 | − 70860-0301-10 · − 70860-0301-25 |
Hospital outpatient (OPPS) status changes
Drug codes whose OPPS status indicator changed between the Q3 2026 and Q4 2026 Addendum B — the difference between being paid separately and being packaged into the administration payment.
| HCPCS | Description | Status | What it means | Rate now |
|---|---|---|---|---|
| A9521 | Technetium tc-99m exametazime, diagnostic, per study dose, up to 25 millicuries | E1 → K | Now paid separately | $927.710 |
| A9600 | Strontium sr-89 chloride, therapeutic, per millicurie | K → E1 | No longer paid separately | — |
| A9608 | Flotufolastat f 18, diagnostic, 1 millicurie | G → K | Pass-through ended; still paid separately | $292.700 |
| J0184 | Injection, amisulpride, 1 mg | G → N | Pass-through ended; now packaged (no separate payment) | — |
| J0209 | Injection, sodium thiosulfate (hope), 100 mg | K → E1 | No longer paid separately | — |
| J0211 | Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote) | K → E1 | No longer paid separately | — |
| J0402 | Injection, aripiprazole (abilify asimtufii), 1 mg | G → K | Pass-through ended; still paid separately | $6.185 |
| J0565 | Injection, bezlotoxumab, 10 mg | K → E1 | No longer paid separately | — |
| J0577 | Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy | G → K | Pass-through ended; still paid separately | $433.167 |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy | G → K | Pass-through ended; still paid separately | $1,732.667 |
| J0716 | Injection, centruroides immune f(ab)2, up to 120 milligrams | E1 → K | Now paid separately | $5,449.649 |
| J0841 | Injection, crotalidae immune f(ab')2 (equine), 120 mg | E1 → K | Now paid separately | $1,084.909 |
| J0891 | Injection, argatroban (accord), not therapeutically equivalent to j0883, 1 mg (for non-esrd use) | K → E2 | No longer paid separately | — |
| J1304 | Injection, tofersen, 1 mg | G → K | Pass-through ended; still paid separately | $164.812 |
| J2374 | Apraclonidine hydrochloride ophthalmic, 1% solution, 0.1 ml | E1 → N | Status changed | — |
| J2799 | Injection, risperidone (uzedy), 1 mg | G → K | Pass-through ended; still paid separately | $26.227 |
| J7214 | Injection, factor viii/von willebrand factor complex, recombinant (altuviiio), per factor viii i.u. | G → K | Pass-through ended; still paid separately | $4.656 |
| J7314 | Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg | K → E1 | No longer paid separately | — |
| J7330 | Autologous cultured chondrocytes, implant | B → E1 | Status changed | — |
| J9161 | Injection, denileukin diftitox-cxdl, 1 mcg | E2 → K | Now paid separately | $12.830 |
| J9232 | Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg | E2 → K | Now paid separately | $0.510 |
| J9296 | Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg | K → E2 | No longer paid separately | — |
| J9302 | Injection, ofatumumab, 10 mg | K → E1 | No longer paid separately | — |
| J9313 | Injection, moxetumomab pasudotox-tdfk, 0.01 mg | K → E1 | No longer paid separately | — |
| J9321 | Injection, epcoritamab-bysp, 0.16 mg | G → K | Pass-through ended; still paid separately | $57.975 |
| J9361 | Injection, efbemalenograstim alfa-vuxw, 0.5 mg | E2 → K | Now paid separately | $121.430 |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | K → E2 | No longer paid separately | — |
| Q5154 | Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg | E2 → K | Now paid separately | $46.610 |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | E2 → K | Now paid separately | $29.720 |
| Q5168 | Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg | E2 → K | Now paid separately | $26.380 |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | E2 → K | Now paid separately | $519.480 |
Pass-through status expiring during the calendar year (18)
- A9601 Flortaucipir f 18 injection, diagnostic, 1 millicurie
- J0174 Lecanemab-irmb, for intravenous injection, 1 mg
- J0177 Injection, aflibercept hd, 1 mg
- J0217 Injection, velmanase alfa-tycv, 1 mg
- J0349 Injection, rezafungin, 1 mg
- J0589 Injection, daxibotulinumtoxina-lanm, 1 unit
- J1323 Injection, elranatamab-bcmm, 1 mg
- J1412 Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes
- J1413 Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
- J2508 Injection, pegunigalsidase alfa-iwxj, 1 mg
- J2782 Injection, avacincaptad pegol, 0.1 mg
- J3055 Injection, talquetamab-tgvs, 0.25 mg
- J3401 Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
- J7165 Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
- J7354 Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
- J9029 Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
- J9286 Injection, glofitamab-gxbm, 2.5 mg
- J9333 Injection, rozanolixizumab-noli, 1 mg
Drug codes new to Addendum B (28)
- C9311 Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (status G)
- C9312 Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg (status G)
- C9313 Injection, pivekimab sunirine-pvzy, 0.01 mg (status G)
- J0014 Cocaine hydrochloride nasal solution (goprelto), 1 mg (status N)
- J0643 Injection, leucovorin calcium, not otherwise specified, 1 mg (status N)
- J0644 Injection, leucovorin calcium (avyxa), 1 mg (status G)
- J0871 Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mg (status K)
- J1757 Injection, tividenofusp alfa-eknm, 1 mg (status K)
- J1818 Injection, pegzilarginase-nbln, 0.05 mg (status K)
- J1946 Injection, furosemide (lasix onyu), 1 mg (status E1)
- J1947 Injection, furosemide (furoscix), 1 mg (status E1)
- J1957 Injection, levetiracetam, 5 mg (status N)
- J1958 Injection, levetiracetam in sodium chloride, 5 mg (status N)
- J3268 Injection, delafloxacin, 1 mg (status E2)
- J3406 Injection, omidubicel-onlv, per therapeutic dose (status K)
- J7524 Mycophenolate mofetil, oral, 5 mg (status N)
- J7526 Injection, mycophenolate mofetil, 5 mg (status N)
- J7529 Mycophenolate mofetil, for suspension, oral, 5 mg (status N)
- J7530 Mycophenolate mofetil (myhibbin), oral suspension, 5 mg (status N)
- J7531 Prednisolone sodium phosphate, orally disintegrating tablet, 1 mg (status E1)
- J9066 Injection, bendamustine hydrochloride (avyxa), 1 mg (status E2)
- J9186 Injection, etoposide (avyxa), 1 mg (status G)
- J9187 Injection, etoposide, 1 mg (status N)
- J9191 Injection, fluorouracil (avyxa), 10 mg (status G)
- J9192 Injection, fluorouracil, 10 mg (status N)
- J9362 Injection, trabectedin, 0.01 mg (status K)
- Q5172 Injection, filgrastim-laha (filkri), biosimilar, 1 microgram (status K)
- Q5173 Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg (status E2)
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.